BlueWhale Bio and Tebubio Partner to Expand Access to Next-Generation T-Cell Manufacturing Technologies Across Europe Joseph Dang / July 16, 2026
BlueWhale Bio Receives FDA Advanced Manufacturing Technology (AMT) Designation for Synecta™ Cell-Derived Nanoparticle Platform Joseph Dang / November 18, 2025
Avantor® and BlueWhale Bio Partner to Accelerate CAR-T Manufacturing with Breakthrough Cell Activation and Expansion Technology Joseph Dang / October 15, 2025
BlueWhale Bio Announces First Patient Dosed in Clinical Trial Using Synecta™ T1 Cell-Derived Nanoparticles Chris Matranga / September 3, 2025
BlueWhaleBio Founded with $18M Financing led by Danaher Ventures to Accelerate Cell Therapy Manufacturing Chris Matranga / September 7, 2023
